David J. Portman - 26 Oct 2026 Form 4 Insider Report for LeonaBio, Inc. (LONA)

Reporting relationship: 10%+ Owner
Issuer ticker: LONA
Reported as of: 26 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Oct 2026, 20:43:08 UTC
Prior SEC filing: 03 Sep 2026
Source filing: View source filing
Reporting owner signature: David J. Portman

Filing notes and source

Key filing fact

David J. Portman filed Form 4 for LeonaBio, Inc. (LONA) on 28 Oct 2026.

Key facts

This page summarizes David J. Portman's Form 4 filing for LeonaBio, Inc. (LONA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Oct 2026, 20:43.

Change

Previous filing in this sequence was filed on 03 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002126186 Primary reporting owner

Portman David J.

Relationship: 10%+ Owner
Address: 250 E. BROAD ST., SUITE 250, COLUMBUS
Signature: David J. Portman
Signature date: 28 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LONA transaction

Common Stock

Purchase

Transaction value
Shares: +3,149,470
Change %
Price: $3149.47^*
Shares after: 3,149,470
Date: 26 Oct 2026
Ownership: See note

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LONA transaction Derivative

Warrant

Purchase

Transaction value
Shares: -5,502,402
Change %: -100%
Price: $3149.47^*
Shares after: 0
Date: 26 Oct 2026
Ownership: See note
Underlying class: Common Stock
Underlying amount: 5,502,402
Exercise price: $0.001000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares are held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. This Form 4 is being filed to report Dr. Portman's voting control over such securities, but Dr. Portman's personal indirect beneficial ownership does not exceed 10% of the stock in the Issuer.

Footnote F2

The Warrant does not expire.

Footnote F3

The Warrant was held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. The Warrant was exercised on October 26, 2026, in part, into 3,149,740 Common Shares of Issuer, and the balance of the Warrant was assigned to Perceptive Xentogeny Venture Fund II, LP as a distribution-in-kind pursuant to a plan of distribution to the Sermonix Pharmaceuticals equity holders. Following the partial exercise and the assignment of the remaining Warrant rights, Sermonix Pharmaceuticals holds 3,149,740 Common Shares of Issuer.